381
views
0
recommends
+1 Recommend
1 collections
    1
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      REPO4EU: The end of drug discovery as we know it

      Published
      proceedings-article
        1
      RExPO22
      2-3 September, 2022
      systems medicine, network pharmacology, drug repurposing
      Bookmark

            Abstract

            Drug repurposing reduces the time and costs of drug development but is often serendipitous and less effective than classical drug discovery [1]. Both, discovery [2] and repurposing, suffer from the same knowledge gap that diseases are mechanistically not understood and treated symptomatically in an imprecise manner [3]. Our team of world-leading scientists overcome this by breakthroughs in advanced bioinformatics and artificial intelligence (AI) on real-world big data to redefine diseases in a mechanism-based manner. Patients are still identified by symptom, but stratified according to causal mechanism, the endotype [4]. REPO4EU unites a group of long-standing collaborators in innovative drug repurposing, who will build together with our partner project, REMEDI4ALL, a comprehensive European/global platform for validated precision drug repurposing open to stakeholders for information, multimedia training, matchmaking and cooperation. Our molecular diagnostic-enabled [5] clinical trials are small, precise, innovatively designed, prioritising, in coordination with regulators, payers and investors, patient-defined outcomes with high safety and operational excellence. This revolutionary new era of organ-agnostic medicine and network pharmacology [6] will allow unprecedented efficacy and cost effectiveness. The promiscuity of small molecules and recently expanded knowledge of protein structures are exploited by cheminformatics and deep learning to repurpose drugs beyond their original target. At any level of the development chain, even for classic projects, REPO4EU provides expertise and matchmaking for freedom-to-operate, intellectual property, reformulation and value-creation, specialised in drug repurposing. Within 5 years, REPO4EU will establish a first-in-class coherent and innovative web-based platform for safe and efficient drug repurposing for all types of high unmet medical need indications to all European researchers and SMEs with a unique Open Science concept, ensuring global medical impact. Finally, within a 2-year interphase, REPO4EU will be converted into a sustainable European infrastructure.

            Content

            Author and article information

            Conference
            30 August 2022
            Affiliations
            [1 ] Department of Pharmacology and Personalised Medicine, School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
            Article
            10.14293/S2199-rexpo22012.v1
            700faf32-ce98-485a-b23a-2f49bb4190c2
            The Author

            Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

            RExPO22
            Maastricht, Netherlands
            2-3 September, 2022
            History
            Product

            ScienceOpen


            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Intellectual property law,Molecular medicine,Bioinformatics & Computational biology,Biotechnology,Pharmacology & Pharmaceutical medicine
            drug repurposing,systems medicine,network pharmacology

            References

            1. Gil Carmen, Martinez Ana. Is drug repurposing really the future of drug discovery or is new innovation truly the way forward? Expert Opinion on Drug Discovery. 1–3. 2021. Informa UK Limited. [Cross Ref]

            2. Scannell Jack W., Blanckley Alex, Boldon Helen, Warrington Brian. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery. Vol. 11(3):191–200. 2012. Springer Science and Business Media LLC. [Cross Ref]

            3. Schork Nicholas J.. Personalized medicine: Time for one-person trials. Nature. Vol. 520(7549):609–611. 2015. Springer Science and Business Media LLC. [Cross Ref]

            4. Langhauser Friederike, Casas Ana I., Dao Vu-Thao-Vi, Guney Emre, Menche Jörg, Geuss Eva, Kleikers Pamela W. M., López Manuela G., Barabási Albert-L., Kleinschnitz Christoph, Schmidt Harald H. H. W.. A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. npj Systems Biology and Applications. Vol. 4(1)2018. Springer Science and Business Media LLC. [Cross Ref]

            5. Elbatreek Mahmoud H., Sadegh Sepideh, Anastasi Elisa, Guney Emre, Nogales Cristian, Kacprowski Tim, Hassan Ahmed A., Teubner Andreas, Huang Po-Hsun, Hsu Chien-Yi, Schiffers Paul M. H., Janssen Ger M., Kleikers Pamela W. M., Wipat Anil, Baumbach Jan, De Mey Jo G. R., Schmidt Harald H. H. W.. NOX5-induced uncoupling of endothelial NO synthase is a causal mechanism and theragnostic target of an age-related hypertension endotype. PLOS Biology. Vol. 18(11)2020. Public Library of Science (PLoS). [Cross Ref]

            6. Nogales Cristian, Mamdouh Zeinab M., List Markus, Kiel Christina, Casas Ana I., Schmidt Harald H.H.W.. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends in Pharmacological Sciences. Vol. 43(2):136–150. 2022. Elsevier BV. [Cross Ref]

            Comments

            Comment on this article